多灶性甲状腺乳头状癌行热消融治疗的疗效与安全性 Meta分析

Meta-Analysis of the Efficacy and Safety of Thermal Ablation Therapy for Multifocal Papillary Thyroid Carcinoma

摘要

目的:探讨热消融治疗 (射频消融、微波消融、激光消融等)在多灶性甲状腺乳头状癌(MPTC)治疗中的疗效与安全性。方法:选择中国知网、万方、维普、中国生物医学文献、PubMed、Cochrane library、Embase、Web of science等国内外文献库检索,检索2014年1月—2025年3月发表的有关 MPTC热消融治疗的文献,筛选符合纳入排除标准的文献并收集数据,采用Stata 14 软件对 MPTC热消融治疗的病灶消失率、并发症发生率、疾病进展发生率及淋巴结转移发生率进行单臂 Meta分析。结果:最终纳入7篇文献共374例患者。Meta分析结果显示,热消融治疗后病灶完全消失率为99.1%(95%CI:96.2%,100.0%),并发症发生率为2.9%(95%CI:1.2%,5.2%),随访期间疾病进展发生率为2.5%(95%CI:0.2%,6.3%),淋巴结转移发生率为0.4%(95%CI:0,1.7%)。结论:热消融治疗 MPTC有较好的疗效,且安全性良好。

Abstract

Objective: To investigate the efficacy and safety of thermal ablation (radiofrequency ablation, microwave ablation, laser ablation, etc.) in the treatment of multifocal papillary thyroid carcinoma (MPTC). Methods: Databases including CNKI, Wanfang Data, VIP, CBM, PubMed, Cochrane Library, Embase, and Web of Science were searched for literatures on thermal ablation for MPTC published from January 2014 to March 2025. Literatures meeting the inclusion and exclusion criteria were screened and data were collected. Stata 14 software was used to perform a single-arm Meta-analysis on the lesion disappearance rate, complication rate, disease progression rate, and lymph node metastasis rate of thermal ablation for MPTC. Results: A total of 7 literatures involving 374 patients were finally included. The Meta-analysis results showed that the complete lesion disappearance rate after thermal ablation was 99.1% (95%CI: 96.2%, 100.0%), the complication rate was 2.9% (95%CI: 1.2%, 5.2%), the disease progression rate during follow-up was 2.5% (95%CI: 0.2%, 6.3%), and the lymph node metastasis rate was 0.4% (95%CI: 0, 1.7%). Conclusion: Thermal ablation is effective and safe in the treatment of MPTC.

关键词

热消融治疗 / 多灶性甲状腺乳头状癌 / Meta分析

Key words

thermal ablation / multifocal papillary thyroid carcinoma (MPTC) / Meta-analysis

参考文献

[1] 中华医学会内分泌学分会, 中华医学会外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 国际内分泌代谢杂志, 2023, 43(2): 149-194.

[2] Kayhan Y, Azizova L, Yilmaz M, et al. Prognostic factors for aggressiveness in subcentimeter papillary thyroid carcinoma: impact of tumor size and lymph node metastases[J]. Arch Endocrinol Metab, 2024, 68: e230422.

[3] Gao Y, Tian M R, Hou X K, et al. Multifocality increases the risk of central compartment lymph node metastasis but is not related to the risk of recurrence and death in papillary thyroid carcinoma[J]. Gland Surg, 2024, 13(12): 2383-2394.

[4] Haugen B R, Alexander E K, Bible K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.

[5] Miyauchi A, Ito Y, Fujishima M, et al. Long—term outcomes of active surveillance and immediate surgery for adult patients with low—risk papillary thyroid microcarcinoma: 30—year experience[J]. Thyroid, 2023, 33(7): 817-825.

[6] Lee E K, Kim M J, Kang S H, et al. 2025 Korean thyroid association clinical management guideline on active surveillance for low—risk papillary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2025, 40(3): 307-341.

[7] Nangadda N, Gondaliya H, Bhat D, et al. Active surveillance of papillary thyroid cancer—a feasibility experience from a tertiary care centre[J]. Indian J Surg Oncol, 2025, 16(3): 743-752.

[8] 陈涛, 张承武, 谭宇彦. 经口腔前庭入路腔镜手术治疗甲状腺癌[J]. 巴楚医学, 2023, 6(3): 15-17.

[9] 中国抗癌协会肿瘤消融治疗专业委员会, 中国临床肿瘤学会(CSCO)肿瘤消融专家委员会, 中国医师协会介入医师分会肿瘤消融专业委员会, 等. 甲状腺乳头状癌热消融治疗专家共识(2024 版)[J]. 中华内科杂志, 2024, 63(4): 355-364.

[10] Sun W, Hu Q H, Liu Z, et al. Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma[J]. Oncol Lett, 2024, 28(5): 544.

[11] Chen D, Qi W J, Xie S L, et al. Investigation of the clonal origin of multifocal papillary thyroid carcinoma according to the X—chromosome inactivation pattern[J]. Oncol Lett, 2019, 17(5): 4695-4700.

[12] Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2007, 92(9): 3511-3516.

[13] Aherne S T, Smyth P C, Flavin R J, et al. Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling[J]. Mol Cancer, 2008, 7: 89.

[14] Muzza M. The clonal origin of multifocal papillary thyroid cancer: intrathyroidal spread or independent tumors[J]. Minerva Endocrinol, 2021, 46(1): 35-44.

[15] García Pascual L, Puig—Jové C, Simó—Servat A, et al. Multifocality of papillary thyroid carcinoma with low risk of recurrence: prevalence, predictive markers, prognostic significance and initial surgical treatment[J]. Endocrinol Diabetes Nutr, 2025, 72(5): 501545.

[16] Seo H J, Kim S Y, Lee Y J, et al. RoBANS 2: a revised risk of bias assessment tool for nonrandomized studies of interventions[J]. Korean J Fam Med, 2023, 44(5): 249-260.

[17] 张锡瑜, 何俊峰, 闫国珍, 等. 微波消融与外科手术治疗多灶性cN0期甲状腺微小癌的临床对比研究[J]. 中国超声医学杂志, 2024, 40(5): 489-492.

[18] 霍胜男, 李国文. 甲状腺微小乳头状癌经皮微波消融与开放手术治疗的效果对比研究[J]. 康颐, 2022, 8: 139-141.

[19] 顾美琴, 奚静, 李尊, 等. 超声引导下微波消融治疗多灶性 T1N0M0甲状腺乳头状癌的可行性研究[J]. 介入放射学杂志, 2024, 33(5): 495-499.

[20] Yan L, Zhang M B, Song Q, et al. Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: a propensity—matched cohort study[J]. Eur Radiol, 2022, 32(2): 1216-1226.

[21] Zhang L, Zhang G P, Zhan W W, et al. The feasibility and efficacy of ultrasound—guided percutaneous laser ablation for multifocal papillary thyroid microcarcinoma[J]. Front Endocrinol, 2022, 13: 921812.

[22] Zhou H D, Yu X Y, Wei Y, et al. A preliminary study on the microwave ablation of multifocal papillary thyroid microcarcinoma[J]. Acad Radiol, 2024, 31(6): 2306-2311.

[23] Dong P, Teng D K, Sui G Q, et al. Long—term efficacy of microwave ablation for multifocal papillary thyroid microcarcinoma: a 5—year follow—up study[J]. Eur Radiol, 2024, 34(1): 715-723.

[24] Zhao Z L, Wang S R, Kuo J, et al. Erratum for: 2024 international expert consensus on US—guided thermal ablation for T1N0M0 papillary thyroid cancer[J]. Radiology, 2025, 315(2): e259009.

[25] Min Y, Wang X, Chen H, et al. Thermal ablation for papillary thyroid microcarcinoma: how far we have come[J]. Cancer Manag Res, 2020, 12: 13369-13379.

[26] Zocchi J, Giugliano G, Mossinelli C, et al. Central neck dissection in papillary thyroid carcinoma: benefits and doubts in the era of thyroid lobectomy[J]. Biomedicines, 2024, 12(10): 2177.

[27] Ha E J, Lee M K, Baek J H, et al. Radiofrequency ablation for recurrent thyroid cancers: 2025 Korean society of thyroid radiology guideline[J]. Korean J Radiol, 2025, 26(1): 10-28.

[28] Hossein P, Leila H M, Mojtaba D. Evaluation of the risk factors of metastasis to central cervical lymph nodes in patients with papillary thyroid carcinoma[J]. Ann Med Surg(Lond), 2024, 86(7): 3847-3851.

[29] Cui L K, Feng D D, Zhu C F, et al. Clinical outcomes of multifocal papillary thyroid cancer: a systematic review and meta—analysis[J]. Laryngoscope Investig Otolaryngol, 2022, 7(4): 1224-1234.

[30] Yan L, Yang Z, Li Y Y, et al. Five—year outcome between radiofrequency ablation vs surgery for unilateral multifocal papillary thyroid microcarcinoma[J]. J Clin Endocrinol Metab, 2023, 108(12): 3230-3238.

基金资助

湖北省卫健委科研项目(2021W337)